Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis

Trial details

Who runs it

NMD Pharma A/S

Trial code

EU 2023-507539-40-00

Record updated

2026. november 9.

Original description

To assess dose response of NMD670 on clinical efficacy as rated by cliniciansRead full original descriptionShow less

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis

To assess dose response of NMD670 on clinical efficacy as rated by clinicians

Inclusion: Participant must be a male or female being ≥18 years, at the time of signing the informed consent; Diagnosis of MG, MGFA class II, III or IV; Documented positive AChR or MuSK antibody test; Participant must be able to swallow tablets; Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg; Female participants who are WOCBP and male participants with partners who are WOCBP must agree to use a highly effective contraception method during the study. Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; Participant is capable of and has given signed informed consent.

Exclusion: Active or untreated thymoma, a history of thymic carcinoma or thymic malignancy (unless deemed cured by adequate treatment with no evidence of recurrence for 5 years or more before screening), a history of thymectomy in the 6 months before screening; Participants received treatment with IMP within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1; Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient’s full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study; Participants with history of poor compliance with relevant MG therapy; Participant with a clinical diagnosis of gout, or with serum uric acid >upper limit of normal (ULN) at screening; Participant with any of the following: a. Abnormal liver function test defined as total bilirubin >1.5× ULN (except for participants with known Gilbert’s syndrome). b. Abnormal liver transaminase levels at baseline and confirmed current or chronic history of liver disease including (but is not limited to) hepatitis virus infections, drug- or alcohol-related liver disease, non alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, α 1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the Investigator. c. Known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones). d. Any renal impairment or kidney abnormalities considered clinically significant by the Investigator at screening; Participant with laboratory test abnormalities at screening considered clinically significant by the Investigator; Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding.

EU CTIS 2023-507539-40-00